Related Experiment Video
Updated: Mar 24, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Robert Pirker1, Martin Filipits2
1Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. robert.pirker@meduniwien.ac.at.
Abstract:
Personalized treatment of patients with advanced non-small-cell lung cancer based on clinical and molecular tumor features has entered clinical routine practice. The 2015 pathological classification of lung cancer mandates immunohistochemical and molecular analysis. Therapeutic strategies focused on inhibition of angiogenesis and growth factor receptor signaling. Inhibitors of angiogenesis and monoclonal antibodies directed against the epidermal growth factor receptor have shown efficacy in combination with chemotherapy. Mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase have become clinically relevant therapeutic targets. Immune checkpoint inhibitors are also entering routine clinical practice. Identification of predictive biomarkers is essential and faces several challenges including tumor heterogeneity and dynamic changes of tumor features over time. Liquid biopsies may overcome some of these challenges in the future.
Insights
Personalized non-small cell lung cancer treatment uses tumor features for targeted therapies. Biomarker identification is key, with liquid biopsies offering future solutions for challenges like tumor heterogeneity.
Area of Science:
- Oncology
- Molecular Pathology
- Personalized Medicine
Background:
- Personalized treatment for advanced non-small cell lung cancer (NSCLC) is now standard practice.
- The 2015 lung cancer classification requires immunohistochemical and molecular analysis.
- Therapeutic strategies target angiogenesis and growth factor receptor signaling.
Purpose of the Study:
- To review current personalized treatment strategies for advanced NSCLC.
- To highlight the role of molecular targets and emerging therapies like immune checkpoint inhibitors.
- To discuss challenges in biomarker identification and the potential of liquid biopsies.
Main Methods:
- Review of current clinical practice and pathological classifications for NSCLC.
- Analysis of therapeutic strategies targeting angiogenesis and specific molecular mutations (EGFR, ALK).
- Discussion of biomarker identification challenges and the emerging role of liquid biopsies.
Main Results:
- Inhibitors of angiogenesis and EGFR-targeted therapies show efficacy with chemotherapy.
- EGFR and ALK mutations are clinically relevant therapeutic targets.
- Immune checkpoint inhibitors are increasingly used in routine practice.
Conclusions:
- Personalized treatment based on molecular features is integral to advanced NSCLC management.
- Accurate biomarker identification is crucial but challenging due to tumor heterogeneity.
- Liquid biopsies present a promising approach to overcome current limitations in biomarker analysis.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers